Alpha Crest Capital Management LLC Amicus Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $350,102 - $454,563	35,652 New	35,652 $372,000
Q1 2022 May 12, 2022	SELL	$7.89 - $12.48 $131,589 - $208,141	-16,678 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$9.82 - $12.44 $519,428 - $658,013	-52,895 Reduced 76.03%	16,678 $193,000
Q3 2021 Nov 10, 2021	BUY	$8.74 - $11.84 $281,532 - $381,390	32,212 Added 86.22%	69,573 $664,000
Q2 2021 Aug 12, 2021	SELL	$8.71 - $10.72 $284,625 - $350,308	-32,678 Reduced 46.66%	37,361 $360,000
Q1 2021 May 13, 2021	BUY	$9.2 - $23.86 $551,770 - $1.43 Million	59,975 Added 595.94%	70,039 $692,000
Q4 2020 Feb 12, 2021	BUY	$13.47 - $24.89 $135,562 - $250,492	10,064 New	10,064 $232,000
Q1 2020 May 13, 2020	SELL	$6.63 - $11.16 $152,370 - $256,479	-22,982 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$7.48 - $10.75 $37,198 - $53,459	4,973 Added 27.61%	22,982 $224,000
Q3 2019 Nov 12, 2019	BUY	$8.02 - $13.25 $144,432 - $238,619	18,009 New	18,009 $144,000

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.53B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.